One gene, many neuropsychiatric disorders: Lessons from Mendelian diseases

Nature Neuroscience

Volumn 17, Issue 6, 2014, Pages 773-781

  Zhu, Xiaolin ^a   Need, Anna C ^a,b   Petrovski, Slavé ^a,c   Goldstein, David B ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN;

ANDROGEN INSENSITIVITY SYNDROME; ATAXIA; ENZYME DEFICIENCY; EPIGENETICS; EXTRAPYRAMIDAL SYNDROME; GAIN OF FUNCTION MUTATION; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC RISK; GENOME IMPRINTING; GENOTYPE PHENOTYPE CORRELATION; HAPLOINSUFFICIENCY; HEMOPHILIA; HUMAN; LONG QT SYNDROME; LOSS OF FUNCTION MUTATION; MENDELIAN DISEASE; MENTAL DISEASE; NEUROLOGIC DISEASE; NONHUMAN; NONSENSE MEDIATED MRNA DECAY; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SPINOCEREBELLAR ATAXIA; X CHROMOSOME INACTIVATION;

ANIMALS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MENDELIAN RANDOMIZATION ANALYSIS; MENTAL DISORDERS; MUTATION;

EID: 84901633682     PISSN: 10976256     EISSN: 15461726     Source Type: Journal    
DOI: 10.1038/nn.3713     Document Type: Review

References (94)

1. Insel, T.R. & Landis, S.C. Twenty-five years of progress: the view from NIMH and NINDS. Neuron 80, 561-567 (2013).
2. Cross-Disorder Group of the Psychiatric Genomics Consoritum & Genetic Risk Outcome of Psychosis Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 381, 1371-1379 (2013).
3. Ruderfer, D.M. et al. Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia. Mol. Psychiatry published online, doi:10.1038/mp.2013.138 (November 26 2013).
4. Williams, H.J. et al. Fine mapping of ZNF804A and genome-wide significant evidence for its involvement in schizophrenia and bipolar disorder. Mol. Psychiatry 16, 429-441 (2011).
5. International Schizophrenia Consortium. et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460, 748-752 (2009).
6. Cross-Disorder Group of the Psychiatric Genomics Consortium. et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat. Genet. 45, 984-994 (2013).
7. Wray, N.R., Lee, S.H. & Kendler, K.S. Impact of diagnostic misclassification on estimation of genetic correlations using genome-wide genotypes. Eur. J. Hum. Genet. 20, 668-674 (2012).
8. Mefford, H.C. et al. Recurrent rearrangements of chromosome 1q21.1 and variable pediatric phenotypes. N. Engl. J. Med. 359, 1685-1699 (2008).
9. Grayton, H.M., Fernandes, C., Rujescu, D. & Collier, D.A. Copy number variations in neurodevelopmental disorders. Prog. Neurobiol. 99, 81-91 (2012).
10. Bijlsma, E.K. et al. Extending the phenotype of recurrent rearrangements of 16p11.2: deletions in mentally retarded patients without autism and in normal individuals. Eur. J. Med. Genet. 52, 77-87 (2009).
11. Ben-Shachar, S. et al. Microdeletion 15q13.3: a locus with incomplete penetrance for autism, mental retardation, and psychiatric disorders. J. Med. Genet. 46, 382-388 (2009).
12. Morrow, E.M. Genomic copy number variation in disorders of cognitive development. J. Am. Acad. Child Adolesc. Psychiatry 49, 1091-1104 (2010).
13. Heinzen, E.L. et al. Rare deletions at 16p13.11 predispose to a diverse spectrum of sporadic epilepsy syndromes. Am. J. Hum. Genet. 86, 707-718 (2010).
14. Ullmann, R. et al. Array CGH identifies reciprocal 16p13.1 duplications and deletions that predispose to autism and/or mental retardation. Hum. Mutat. 28, 674-682 (2007).
15. Bachmann-Gagescu, R. et al. Recurrent 200-kb deletions of 16p11.2 that include the SH2B1 gene are associated with developmental delay and obesity. Genet. Med. 12, 641-647 (2010).
16. Stefansson, H. et al. Large recurrent microdeletions associated with schizophrenia. Nature 455, 232-236 (2008).
17. Digilio, M.C. et al. Congenital heart defects in recurrent reciprocal 1q21.1 deletion and duplication syndromes: rare association with pulmonary valve stenosis. Eur. J. Med. Genet. 56, 144-149 (2013).
18. Rosenfeld, J.A. et al. Proximal microdeletions and microduplications of 1q21.1 contribute to variable abnormal phenotypes. Eur. J. Hum. Genet. 20, 754-761 (2012).
19. Kirov, G. et al. Neurexin 1 (NRXN1) deletions in schizophrenia. Schizophr. Bull. 35, 851-854 (2009).
20. Rujescu, D. et al. Disruption of the neurexin 1 gene is associated with schizophrenia. Hum. Mol. Genet. 18, 988-996 (2009).
21. Friedman, J.I. et al. CNTNAP2 gene dosage variation is associated with schizophrenia and epilepsy. Mol. Psychiatry 13, 261-266 (2008).
22. Ching, M.S. et al. Deletions of NRXN1 (neurexin-1) predispose to a wide spectrum of developmental disorders. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 153B, 937-947 (2010).
23. Gregor, A. et al. Expanding the clinical spectrum associated with defects in CNTNAP2 and NRXN1. BMC Med. Genet. 12, 106 (2011).
24. Iossifov, I. et al. De novo gene disruptions in children on the autistic spectrum. Neuron 74, 285-299 (2012).
25. Neale, B.M. et al. Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature 485, 242-245 (2012).
26. O'Roak, B.J. et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature 485, 246-250 (2012).
27. Sanders, S.J. et al. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature 485, 237-241 (2012).
28. de Ligt, J. et al. Diagnostic exome sequencing in persons with severe intellectual disability. N. Engl. J. Med. 367, 1921-1929 (2012).
29. Rauch, A. et al. Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study. Lancet 380, 1674-1682 (2012).
30. Xu, B. et al. De novo gene mutations highlight patterns of genetic and neural complexity in schizophrenia. Nat. Genet. 44, 1365-1369 (2012).
31. Epi4K Consortium. et al. De novo mutations in epileptic encephalopathies. Nature 501, 217-221 (2013).
32. Sullivan, P.F., Daly, M.J. & O'Donovan, M. Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nat. Rev. Genet. 13, 537-551 (2012).
33. Goldstein, D.B. et al. Sequencing studies in human genetics: design and interpretation. Nat. Rev. Genet. 14, 460-470 (2013).
34. Stessman, H.A., Bernier, R. & Eichler, E.E. A genotype-first approach to defining the subtypes of a complex disease. Cell 156, 872-877 (2014).
35. McKusick, V.A. Phenotypic diversity of human diseases resulting from allelic series. Am. J. Hum. Genet. 25, 446-456 (1973).
36. Stearns, F.W. One hundred years of pleiotropy: a retrospective. Genetics 186, 767-773 (2010).
37. Mackay, T.F. Epistasis and quantitative traits: using model organisms to study gene-gene interactions. Nat. Rev. Genet. 15, 22-33 (2014).
38. Online Mendelian Inheritance in Man. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University http://omim.org/ (accessed 2 September 2013).
39. Gibbons, R.J. & Higgs, D.R. Molecular-clinical spectrum of the ATR-X syndrome. Am. J. Med. Genet. 97, 204-212 (2000).
40. Badens, C. et al. Mutations in PHD-like domain of the ATRX gene correlate with severe psychomotor impairment and severe urogenital abnormalities in patients with ATRX syndrome. Clin. Genet. 70, 57-62 (2006).
41. Revesz, T. et al. Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. Acta Neuropathol. 118, 115-130 (2009).
42. Heinzen, E.L. et al. De novo mutations in ATP1A3 cause alternating hemiplegia of childhood. Nat. Genet. 44, 1030-1034 (2012).
43. Caputo, V. et al. A restricted spectrum of mutations in the SMAD4 tumor-suppressor gene underlies Myhre syndrome. Am. J. Hum. Genet. 90, 161-169 (2012).
44. Le Goff, C. et al. Mutations at a single codon in Mad homology 2 domain of SMAD4 cause Myhre syndrome. Nat. Genet. 44, 85-88 (2012).
45. Blencowe, B.J. Alternative splicing: new insights from global analyses. Cell 126, 37-47 (2006).
46. Shekarabi, M. et al. Mutations in the nervous system-specific HSN2 exon of WNK1 cause hereditary sensory neuropathy type II. J. Clin. Invest. 118, 2496-2505 (2008).
47. Wilson, F.H. et al. Human hypertension caused by mutations in WNK kinases. Science 293, 1107-1112 (2001).
48. Gulsuner, S. et al. Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network. Cell 154, 518-529 (2013).
49. Willsey, A.J. et al. Coexpression networks implicate human midfetal deep cortical projection neurons in the pathogenesis of autism. Cell 155, 997-1007 (2013).
50. Parikshak, N.N. et al. Integrative functional genomic analyses implicate specific molecular pathways and circuits in autism. Cell 155, 1008-1021 (2013).
51. Ichinose, H. et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat. Genet. 8, 236-242 (1994).
52. Furukawa, Y. et al. Dystonia with motor delay in compound heterozygotes for GTP-cyclohydrolase I gene mutations. Ann. Neurol. 44, 10-16 (1998).
53. Koch, J. et al. Molecular cloning and characterization of a full-length complementary DNA encoding human acid ceramidase. Identification Of the first molecular lesion causing Farber disease. J. Biol. Chem. 271, 33110-33115 (1996).
54. Zhou, J. et al. Spinal muscular atrophy associated with progressive myoclonic epilepsy is caused by mutations in ASAH1. Am. J. Hum. Genet. 91, 5-14 (2012).
55. Otto, E.A. et al. Hypomorphic mutations in meckelin (MKS3/TMEM67) cause nephronophthisis with liver fibrosis (NPHP11). J. Med. Genet. 46, 663-670 (2009).
56. Mercuri, E. et al. Congenital muscular dystrophies with defective glycosylation of dystroglycan: a population study. Neurology 72, 1802-1809 (2009).
57. Kanai, K. et al. Physicochemical property changes of amino acid residues that accompany missense mutations in SCN1A affect epilepsy phenotype severity. J. Med. Genet. 46, 671-679 (2009).
58. Waxman, S.G. & Dib-Hajj, S.D. Erythromelalgia: a hereditary pain syndrome enters the molecular era. Ann. Neurol. 57, 785-788 (2005).
59. Cox, J.J. et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature 444, 894-898 (2006).
60. de Brouwer, A.P. et al. PRPS1 mutations: four distinct syndromes and potential treatment. Am. J. Hum. Genet. 86, 506-518 (2010).
61. Frischmeyer, P.A. & Dietz, H.C. Nonsense-mediated mRNA decay in health and disease. Hum. Mol. Genet. 8, 1893-1900 (1999).
62. Malan, V. et al. Distinct effects of allelic NFIX mutations on nonsense-mediated mRNA decay engender either a Sotos-like or a Marshall-Smith syndrome. Am. J. Hum. Genet. 87, 189-198 (2010).
63. Khajavi, M. et al. Curcumin treatment abrogates endoplasmic reticulum retention and aggregation-induced apoptosis associated with neuropathy-causing myelin protein zero-truncating mutants. Am. J. Hum. Genet. 77, 841-850 (2005).
64. Inoue, K. et al. Molecular mechanism for distinct neurological phenotypes conveyed by allelic truncating mutations. Nat. Genet. 36, 361-369 (2004).
65. Nelson, D.L., Orr, H.T. & Warren, S.T. The unstable repeats-three evolving faces of neurological disease. Neuron 77, 825-843 (2013).
66. La Spada, A.R., Wilson, E.M., Lubahn, D.B., Harding, A.E. & Fischbeck, K.H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352, 77-79 (1991).
67. Parvari, R. et al. Mutation of TBCE causes hypoparathyroidism- retardation-dysmorphism and autosomal recessive Kenny-Caffey syndrome. Nat. Genet. 32, 448-452 (2002).
68. Johnson, J.O. et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 68, 857-864 (2010).
69. Tran-Viet, K.N. et al. Mutations in SCO2 are associated with autosomal-dominant high-grade myopia. Am. J. Hum. Genet. 92, 820-826 (2013).
70. Parsons, D.W. et al. Intragenic telSMN mutations: frequency, distribution, evidence of a founder effect, and modification of the spinal muscular atrophy phenotype by cenSMN copy number. Am. J. Hum. Genet. 63, 1712-1723 (1998).
71. Lupski, J.R., Belmont, J.W., Boerwinkle, E. & Gibbs, R.A. Clan genomics and the complex architecture of human disease. Cell 147, 32-43 (2011).
72. Nadeau, J.H. Modifier genes in mice and humans. Nat. Rev. Genet. 2, 165-174 (2001).
73. Wong, A.H., Gottesman, I.I. & Petronis, A. Phenotypic differences in genetically identical organisms: the epigenetic perspective. Hum. Mol. Genet. 14, R11-R18 (2005).
74. Raj, A., Rifkin, S.A., Andersen, E. & van Oudenaarden, A. Variability in gene expression underlies incomplete penetrance. Nature 463, 913-918 (2010).
75. Burga, A. & Lehner, B. Beyond genotype to phenotype: why the phenotype of an individual cannot always be predicted from their genome sequence and the environment that they experience. FEBS J. 279, 3765-3775 (2012).
76. Tsankova, N., Renthal, W., Kumar, A. & Nestler, E.J. Epigenetic regulation in psychiatric disorders. Nat. Rev. Neurosci. 8, 355-367 (2007).
77. Jiang, Y.H., Bressler, J. & Beaudet, A.L. Epigenetics and human disease. Annu. Rev. Genomics Hum. Genet. 5, 479-510 (2004).
78. Chess, A. Random and non-random monoallelic expression. Neuropsychopharmacology 38, 55-61 (2013).
79. Antonellis, A. et al. Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V. Am. J. Hum. Genet. 72, 1293-1299 (2003).
80. White, J.K. et al. Genome-wide generation and systematic phenotyping of knockout mice reveals new roles for many genes. Cell 154, 452-464 (2013).
81. Bilgüvar, K. et al. Whole-exome sequencing identifies recessive WDR62 mutations in severe brain malformations. Nature 467, 207-210 (2010).
82. McCarroll, S.A. & Hyman, S.E. Progress in the genetics of polygenic brain disorders: significant new challenges for neurobiology. Neuron 80, 578-587 (2013).
83. Blair, D.R. et al. A nondegenerate code of deleterious variants in mendelian Loci contributes to complex disease risk. Cell 155, 70-80 (2013).
84. Darnell, J.C. et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 146, 247-261 (2011).
85. Fromer, M. et al. De novo mutations in schizophrenia implicate synaptic networks. Nature 506, 179-184 (2014).
86. Petrovski, S., Wang, Q., Heinzen, E.L., Allen, A.S. & Goldstein, D.B. Genic intolerance to functional variation and the interpretation of personal genomes. PLoS Genet. 9, e1003709 (2013).
87. Adzhubei, I.A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248-249 (2010).
88. Zaidi, S. et al. De novo mutations in histone-modifying genes in congenital heart disease. Nature 498, 220-223 (2013).
89. Girard, S.L. et al. Increased exonic de novo mutation rate in individuals with schizophrenia. Nat. Genet. 43, 860-863 (2011).
90. Cutting, G.R. Modifier genes in Mendelian disorders: the example of cystic fibrosis. Ann. NY Acad. Sci. 1214, 57-69 (2010).
91. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013).
92. Hou, Z. et al. Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proc. Natl. Acad. Sci. USA 110, 15644-15649 (2013).
93. Spira, M.E. & Hai, A. Multi-electrode array technologies for neuroscience and cardiology. Nat. Nanotechnol. 8, 83-94 (2013).
94. Venkatachalam, V. et al. Flash memory: photochemical imprinting of neuronal action potentials onto a microbial rhodopsin. J. Am. Chem. Soc. 136, 2529-2537 (2014).